Cephalon corporate affairs director
Pennsylvania Bio President Fritz Bittenbender to join Cephalon as senior director of corporate affairs responsible for external corporate affairs and state government relations, the company says. He will join Cephalon in October and will report to VP-Corporate Development & Public Affairs Robert Grupp. Bittenbender moves to Cephalon after three years at the helm of the biotech trade group Pennsylvania Bio. The association's board of directors has commenced a search for a new president...
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.